A Progressive Digital Media business

COMPANY PROFILE

DexCom Inc

REFERENCE CODE: BD2E5033-961C-48ED-A0B0-3EAED86A0FE5

PUBLICATION DATE: 01 Sep 2018
www.marketline.com
COPYRIGHT MARKETLINE. THIS CONTENT IS A LICENSED PRODUCT AND IS NOT TO BE PHOTOCOPIED OR DISTRIBUTED
DexCom Inc
TABLE OF CONTENTS

TABLE OF CONTENTS

Company Overview ........................................................................................................3

Key Facts ......................................................................................................................... 3
Tickers ............................................................................................................................. 4
Business Description .....................................................................................................5
Corporate Strategy .........................................................................................................7
Business Segment..........................................................................................................8
History ............................................................................................................................. 9
Key Employees .............................................................................................................15
Key Employee Biographies .........................................................................................16
Major Products & Services ..........................................................................................17
SWOT Analysis .............................................................................................................18
Top Competitors ...........................................................................................................22
Company View ..............................................................................................................23
Locations And Subsidaries .........................................................................................26
Financial Overview .......................................................................................................27

DexCom Inc Page 2

© MarketLine
DexCom Inc
Company Overview

Company Overview

COMPANY OVERVIEW
DexCom Inc (DexCom) is a medical device company that performs design, development and
commercialization of continuous glucose monitoring systems for ambulatory and in-hospital use. The
company’s major products include DexCom G4, DexCom G4 Platinum and other continuous glucose
monitoring systems. DexCom’s in-hospital product, GlucoClear, is a blood-based in-vivo automated
glucose monitoring system. It also provides training and support services. DexCom offer its products to
endocrinologists, physicians, diabetes educators and others. The company distributes its products in the
US, Canada, Australia, New Zealand, Europe, Asia, Latin America and the Middle East through direct
sales force and a network of distributors. DexCom is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$718.5 million for the fiscal year ended December
2017 (FY2017), an increase of 25.3% over FY2016. The operating loss of the company was US$42.5
million in FY2017, compared to an operating loss of US$63.9 million in FY2016. The net loss of the
company was US$50.2 million in FY2017, compared to a net loss of US$65.6 million in FY2016.

The company reported revenues of US$266.7 million for the third quarter ended September 2018, an
increase of 10% over the previous quarter.
Key Facts

KEY FACTS

Head Office DexCom Inc

6340 Sequence Drive
San Diego
California
San Diego
California
USA
Phone 1 858 2000200
Fax 1 302 6365454
Web Address www.dexcom.com
Revenue / turnover (USD Mn) 718.5
Financial Year End December
Employees 2,290
NASDAQ Ticker DXCM

DexCom Inc Page 3

© MarketLine
DexCom Inc
Company Overview

Tickers

TICKERS
DXCM

DexCom Inc Page 4

© MarketLine
DexCom Inc
Company Overview

Business Description

BUSINESS DESCRIPTION
DexCom Inc (DexCom) is a provider of continuous glucose monitoring (CGM) systems for ambulatory use
by people with diabetes and healthcare providers in the hospital for the treatment of diabetic and non-
diabetic patients.

The company offers two product lines, namely, Ambulatory product line and In-Hospital product line.

DexCom’s Ambulatory product line includes Seven Plus, DexCom G4, DexCom G4 Platinum, DexCom
Share System and DexCom G5 Mobile. The Seven Plus CGM system is a short-term continuous glucose
monitoring system (STS) device designed for seven days of continuous uninterrupted use. The devices
help in measuring the glucose levels, and provide up to 288 glucose measurements a day and
incorporate additional user interface and algorithm enhancements that are intended to make its glucose
monitoring function accurate and customizable. DexCom’s G4 Platinum provides continuous glucose
monitoring with wireless reporting every five minutes. It tracks glucose levels continuously for seven days
throughout the 24-hour period using wireless technology. It enables users to view their glucose levels on
demand. The system allows diabetics to program personalized information, such as glucose targets and
alerts. The system has an alarm feature to alert the user if glucose levels rise or fall to dangerous levels.
DexCom G4 Platinum (Pediatric) is the only CGM system approved for kids aged two years and above.

DexCom also offers G4 Platinum Receiver with Share that has built in bluetooth wireless communication.
It enables remote viewing and sharing of glucose levels, trends and data between the person with
diabetes and its family members and friends. DexCom mobile application is also available on iOS and
Android platform.

DexCom’s CGM system consists of three parts, which comprise a sensor, a transmitter and a receiver.
The sensor is flexible and tiny, which easily fits into the insertion needle completely. The product is also
provided with a detachable and disposable applicator. The transmitter is water resistant and small in
nature. It transmits glucose signals wirelessly. It also provides in sensor data processing. The receiver
supports an easy viewing glucose trends in different colors.

The company’s in-hospital product GlucoClear is a blood-based in-vivo automated glucose monitoring
system developed in collaboration with Edwards Lifesciences. DexCom entered into an exclusive
agreement with Edwards to develop jointly and market a specific product platform for the in-hospital
glucose monitoring market. The company received CE Mark approval for GlucoClear glucose monitoring
system.

The company also develops DexCom SHARE remote monitoring system. Through secure wireless
connections, DexCom SHARE notifies another person of a user's G4 Platinum sensor glucose
information when the G4 Platinum Receiver is docked in the DexCom SHARE Cradle. It provides
secondary notification and does not replace real time continuous glucose monitoring or standard home
blood glucose monitoring.

Apart from these products, the company also offers data transfer service through its subsidiary,
SweetSpot Diabetes Care, Inc. It is a health data company with focus on improving the use of data in the

DexCom Inc Page 5

© MarketLine
DexCom Inc
Company Overview

treatment of diabetes. It specializes in turning raw output from patient devices into reports that are useful
for researchers, health care providers, and patients. SweetSpot’s software provides an advanced cloud-
based platform for healthcare providers, individuals and researchers.

The company’s research and development activities are focused on the commercialization of its
ambulatory continuous glucose monitoring systems. In FY2017, the company spent US$185.4 million on
its research and development activities, which as a percentage of revenue stood at 25.8%.

DexCom conducts its sales and marketing operations through direct sales personnel and distributors. The
company has a manufacturing facility in San Diego, California.

DexCom Inc Page 6

© MarketLine
DexCom Inc
Company Overview

Corporate Strategy

CORPORATE STRATEGY
DexCom seeks to become a leading provider of continuous glucose monitoring systems and related
products through the development of innovative products that integrate the continuous glucose monitoring
technologies into insulin pump delivery systems of the respective partners. In addition, the company
develops products through internal development, strong partner relationships and strategic alliances. The
key steps in achieving its objective include

Establishing and maintaining its technology platform as the leading approach to continuous glucose
monitoring and leverage its development expertise to rapidly bring products to market, including for
expanded indications.

Driving the adoption of its ambulatory products through a direct sales and marketing effort, as well as key
distribution arrangements.

Driving additional adoption through technology integration partnerships such as its current partnerships
with Eli Lilly, Insulet, Tandem and others.

Seeking broad coverage policies and reimbursement for its products from private third-party payors and
national health systems such as Medicare.

Driving increased utilization and adoption of its products through a cloud-based data repository platform
that enables people with diabetes to aggregate and analyze data from numerous diabetes devices and
share the data with their healthcare providers.

Expanding the use of its products to other patient care settings and patient demographics, including
people with Type 2 diabetes.

Providing a high level of customer support, service and education.

Pursuing the highest safety and quality levels for its products.

DexCom Inc Page 7

© MarketLine
DexCom Inc
Company Overview

Business Segment

BUSINESS SEGMENT

Geography

The US

Performance

Reported revenue of US$596.2 million for FY2017, which grew 19.8% YoY, and recorded CAGR of
31.0% during 2015-17.

The US accounted for 83.0% of the company's revenue in FY2017.

Outside of the US

Performance

Reported revenue of US$122.3 million for FY2017, which grew 61.3% YoY, and recorded CAGR of
49.7% during 2015-17. Outside of the US accounted for 17.0% of the company's revenue in FY2017.

DexCom Inc Page 8

© MarketLine
DexCom Inc
Company Overview

History

HISTORY

Contracts/Agreements

Year: 2018

In January, the company entered into an agreement with UnitedHealthcare to perform individualized
glucose management pilot program using UnitedHealthcare's novel digital wearable technology to enable
people with type 2 diabetes to better manage their condition.

Acquisitions/Mergers/Takeovers

Year: 2018

In August, the company acquired TypeZero Technologies, Inc.

Contracts/Agreements

Year: 2017

In November, the company signed a development agreement with Eli Lilly and Co (Lilly) to include
Dexcom CGM into Lilly's connected diabetes ecosystem. According to the terms of the agreement, the
companies will combine Lilly's smart insulin delivery devices with Dexcom CGM to enhance diabetes
management.

Contracts/Agreements

Year: 2017

In September, DexCom entered into collaboration with Fitbit to develop and market products to help
people better manage their diabetes and get a comprehensive picture of their overall health with mobile
tools.

Corporate Changes/Expansions

Year: 2016

In June, Dexcom plan to open up a new state of the art manufacturing facility in Arizona for its glucose
monitoring business.

Commercial Operation

Year: 2016

DexCom Inc Page 9

© MarketLine
DexCom Inc
Company Overview

In June, Dexcom's researchers informed CGM technology improvement towards accuracy and reliability,
to use CGM as their primary source for glucose information for Type 1 Diabetes.

Plans/Strategy

Year: 2016

In June, Dexcom planned a new manufacturing facility with latest technologies in Greater Phoenix,
Arizona for its continuous glucose monitoring business.

Corporate Changes/Expansions

Year: 2016

In November, Dexcom set up a new HQ in Edinburgh.

Corporate Changes/Expansions

Year: 2016

In November, Dexcom opened a new headquarters in Scotland.

Regulatory Approval

Year: 2015

In January, the company's G4 PLATINUM Continuous Glucose Monitoring System with Share has
received U.S. Food and Drug Administration approval .

Contracts/Agreements

Year: 2015

In June, Glooko Inc. entered into an agreement with Dexcom, Inc.and Insulet Corporation to unify all
diabetes relevant device data into a single, unified platform to enable both patients and healthcare
providers to improve health outcomes.

Contracts/Agreements

Year: 2015

In July, Tandem Diabetes Care, Inc. entered into non-exclusive Development Agreement with Dexcom,
Inc. for integration of future generation Tandem insulin pumps with the Dexcom G5 and G6 continuous
glucose monitoring systems.

DexCom Inc Page 10

© MarketLine
DexCom Inc
Company Overview

Contracts/Agreements

Year: 2015

In August, DexCom entered into an agreement with the life sciences team at Google for jointly
development of a series of next-generation CGM products.

Regulatory Approval

Year: 2015

In August, the company received the U.S. Food and Drug Administration (FDA) approval for the Dexcom
G5 Mobile Continuous Glucose Monitoring (CGM) System.

Contracts/Agreements

Year: 2015

In September, the company and Edwards Lifesciences Corp entered into agreement to develop
continuous glucose monitoring technology for use in hospitals.

Corporate Awards

Year: 2014

In April, the company has been awarded as the most innovative company within the healthcare industry
by Fast Company.

Regulatory Approval

Year: 2014

In February, the company received the US FDA approval for its CGM device: DexCom G4 Platinum
(Pediatric) for use in children aged 2 to 17 years with diabetes.

Regulatory Approval

Year: 2014

In June, the company received U.S. Food and Drug Administration (FDA) approval for its Dexcom G4
PLATINUM Professional CGM.

Contracts/Agreements

DexCom Inc Page 11

© MarketLine
DexCom Inc
Company Overview

Year: 2014

In August, the company entered into an agreement with Insulet to develop a CGM-Integrated Personal
Diabetes Manager.

Plans/Strategy

Year: 2014

In August, Dexcom and Asante Solutions planned to enable the Dexcom mobile app platform, which is
currently under development, to integrate and display insulin data from the Asante Snap Insulin Pump.

Regulatory Approval

Year: 2013

In February, the company received CE Mark approval for DexCom G4 Platinum (Pediatric).

Research and Development

Year: 2013

The company submitted a PMA supplement to the US FDA seeking approval for the new DexCom
SHARE remote monitoring system.

Contracts/Agreements

Year: 2013

In January, Tandem Diabetes Care announced development and commercialization agreement with
Dexcom, Inc. to include Dexcom's newest continuous glucose monitoring system, the G4 PLATINUM.

Regulatory Approval

Year: 2012

In July, the company received CE Mark approval for DexCom G4 system.

Contracts/Agreements

Year: 2012

The company signed a joint product development agreement with Tandem Diabetes Care, Inc.

Regulatory Approval

DexCom Inc Page 12

© MarketLine
DexCom Inc
Company Overview

Year: 2012

In October, the company received the US FDA approval for DexCom G4 Platinum.

Acquisitions/Mergers/Takeovers

Year: 2012

In February, the company acquired SweetSpot Diabetes Care, Inc., a healthcare-focused information
technology company.

Others

Year: 2010

In June, the company received a warning letter from the US FDA. which cites a deviation related to MDR
reporting for complaints involving sensor wire fractures underneath a patient's skin and recommends
some specific changes to the company's warning and precaution statements in its product labeling.

Contracts/Agreements

Year: 2009

In May, the company entered into an agreement with Edwards Lifesciences Corporation to jointly develop
and market GlucoClear, an in-hospital automatic blood glucose monitoring system.

Regulatory Approval

Year: 2009

In October, the company received CE Mark approval for Seven Plus continuous glucose monitoring
system.

Contracts/Agreements

Year: 2008

The company entered into a distribution agreements with RGH Enterprises, Inc., for selling its durable
systems and disposable units.

Contracts/Agreements

Year: 2008

DexCom Inc Page 13

© MarketLine
DexCom Inc
Company Overview

In November, The company entered into an agreement with Edwards Lifesciences Corporations to
develop products for continuously monitoring blood glucose levels in patients hospitalized for a variety of
conditions.

Regulatory Approval

Year: 2008

In December, the company received CE Mark approval for Seven CGM system.

Contracts/Agreements

Year: 2008

The company signed a joint development agreement with Animas Corporation and Insulet Corporation.

Contracts/Agreements

Year: 2008

In January, the company entered into a joint development agreement with Animas Corporation to
integrate its continuous glucose monitoring (CGM) technology into Animas insulin pumps.

New Product Approvals

Year: 2006

Dexcom received the US FDA approval for STS continuous glucose monitoring system and DM consumer
data manager.

Incorporation/Establishment

Year: 1999

DexCom, Inc. was founded.

DexCom Inc Page 14

© MarketLine
DexCom Inc
Company Overview

Key Employees

KEY EMPLOYEES

Name Job Title Board

Kevin Sayer Chairman, Chief Executive Officer, Executive Board
Director, President
Rick Doubleday Executive Vice President, Chief Senior Management
Commercial Officer
Patrick Murphy Chief Compliance Officer, General Senior Management
Counsel
Quentin Blackford Chief Financial Officer Senior Management
Eric Topol, M.D. Director Non Executive Board
Barbara E. Kahn Director Non Executive Board
Jay S. Skyler, M.D. Director Non Executive Board
Steven R. Altman Director Non Executive Board
Mark G. Foletta Director Non Executive Board
Nick Augustinos Director Non Executive Board
Richard Collins Director Non Executive Board
Andrew K. Balo Executive Vice President-Clinical, Senior Management
Regulatory and Quality
Steven R. Pacelli Executive Vice President-Corporate Senior Management
Development
Don Abbey Executive Vice President-Quality & Senior Management
Information Technology
Jacob Leach General Manager-Europe, Middle East Senior Management
& Africa
Annika Jimenez Senior Vice President-Data Senior Management
Claudia Graham Senior Vice President-Global Access Senior Management
Heather Ace Senior Vice President-Human Senior Management
Resources
Jeffrey C. Moy Senior Vice President-Operations Senior Management

DexCom Inc Page 15

© MarketLine
DexCom Inc
Company Overview

Key Employee Biographies

KEY EMPLOYEE BIOGRAPHIES

Kevin Sayer

Board:Executive Board
Job Title:Chairman, Chief Executive Officer, Director, President
Since:2015
Age:60

Mr. Kevin Sayer has been the Chairman since 2018 and served as President, Chief Executive Officer,
Director of DexCom since January 2015. Previously, Mr. Sayer has served as the President and the Chief
Operating Officer of the company. Between 2007 and 2010, he served as the Chief Financial Officer of
Biosensors International Group, Ltd. Prior to joining Biosensors, Mr. Sayer served as an independent
healthcare and medical technology industry consultant from 2005 to 2007.

Rick Doubleday

Board:Senior Management
Job Title:Executive Vice President, Chief Commercial Officer
Since:2015
Age:55

Rick Doubleday has been the Executive Vice President, Chief Commercial Officer of the company since
January 2015. Prior to this, he served as Vice President of Sales of the company from June 2009. Before
joining Dexcom, he worked with Johnson & Johnson.

DexCom Inc Page 16

© MarketLine
DexCom Inc
Company Overview

Major Products & Services

MAJOR PRODUCTS & SERVICES

DexCom is a US-based company that carries out the design, development and commercialization of
continuous glucose monitoring systems for ambulatory and in-hospital use. The major products and
services of the company includes:

Products:

Ambulatory Product Line:

SEVEN PLUS
DexCom G4
DexCom G4 PLATINUM
DexCom Share System
DexCom G5 Mobile

In-Hospital Product:
GlucoClear In-Vivo Automated Glucose Monitoring System

Services:

Support
Training

Brands:

SEVEN
DexCom
GlucoClear
SHARE

DexCom Inc Page 17

© MarketLine
DexCom Inc
Company Overview

SWOT Analysis

SWOT ANALYSIS
DexCom Inc (DexCom) develops and markets continuous glucose monitoring systems for use by persons
with diabetes. An extensive sales network and strong research and development focus are its major
strengths even as history of operating loss is a major cause of concern for the company. Although stiff
competition, dependence on distributors and patent expiry could negatively affect its growth prospects,
DexCom could benefit from the strategic collaborations and growing diabetic care market.

Strength Weakness

Proprietary Technology History of Operating Losses

Agreements and Collaborations
Research and Development Focus
Opportunity Threat

Strategic Agreements Government Regulations

Growing Diabetes Care Devices Market Stiff Competition
Uncertain R&D Outcomes

Strength

Proprietary Technology

Proprietary technologies provide a competitive advantage to the company. Harnessing its proprietary
technologies including sensor technology, receiver and transmitter technology, algorithms, software,
implant tools and sealed protective housings, DexCom develops innovative solutions for continues
glucose monitoring. The company’s sensors include biomaterials, electrochemistry, membrane systems
and low power microelectronics. Its membrane technology consists of multiple polymer layers which are
configured to selectively allow the mix of glucose and oxygen through the membrane, react with a
glucose specific enzyme to create low level electrical signal, measured in pico-amperes. The company
use radiofrequency telemetry to wirelessly transmit information from sensor to receiver, which processes
and displays real-time and trended glucose values. Proprietary algorithms and software are programmed
into the receiver to process glucose data and display it on a user-friendly graphical user interface.

Agreements and Collaborations

The company entered into certain partnerships and agreements that are aimed at enhancing its business
operations and existing product line. This could help the company maintain its competitive position in the
industry. The company entered into a definitive collaboration agreement with Edwards Lifesciences
Corporation, to develop products for continuously monitoring blood glucose levels. Through this
agreement, the company developed continuous glucose sensing technology for critically ill diabetic and
non-diabetic patients. The company entered into an agreement with Tandem Diabetes Care, Inc., to

DexCom Inc Page 18

© MarketLine
DexCom Inc
Company Overview

integrate continuous glucose monitoring technology into the insulin pump product offering of Tandem.
Through this agreement, the company integrates best-in-class diabetes care to patients.

Research and Development Focus

Its R&D activities focus on improving existing products and developing new products for ambulatory use
by people with diabetes and healthcare providers in the hospital for the treatment of diabetic and non-
diabetic patients. Its research and development expenses consisting of engineering and research
expenses related to its continuous glucose monitoring technology, clinical trials, regulatory expenses,
quality assurance programs, materials and products for clinical trials increased from US$156.1 million in
FY2016 to US$185.4 million in FY2017. The company’s expertise in R&D enabled it to obtain various
patents in core membrane and sensor technologies. As of January 2018, the company held 391 issued
US patents, 42 granted European patents, and 231 additional US patent applications pending, 56
European patent applications pending, and 21 other international applications.

Weakness

History of Operating Losses

The company carries a history of significant and continued operating losses, which is a serious cause for
concern to the company's growth. DexCom's growing deficit and operating loss are serious causes for
concern as the company could face problems in financing its research projects and will also feel the
pressure of meeting its operational requirements. The company reported operating loss of US$42.5
million in FY2017, and net loss of US$50.2 million in FY2017. This was mainly due to increase in
operating expenses from US$442.3 million in FY2016 to US$534.6 million in FY2017. As of December
31, 2017, the company's accumulated deficit was US$671.8 million.

Opportunity

Strategic Agreements

The company entered into strategic agreements for enhancing its business operations and existing
product line. In January 2018, DexCom entered into an agreement with UnitedHealthcare to perform
individualized glucose management pilot program using UnitedHealthcare's novel digital wearable
technology to help people with Type 2 diabetes manage their condition in real time. In November 2017,
the company signed a development agreement with Eli Lilly and Co (Lilly) to include Dexcom CGM into
Lilly's connected diabetes ecosystem. According to the terms of the agreement, the companies will
combine Lilly's smart insulin delivery devices with Dexcom CGM to enhance diabetes management. In
September 2017, DexCom entered into collaboration with Fitbit to develop and market products to help
people better manage their diabetes and get a comprehensive picture of their overall health with mobile
tools.

Growing Diabetes Care Devices Market

DexCom Inc Page 19

© MarketLine
DexCom Inc
Company Overview

Food habits, obesity, lifestyle changes and hypertension are contributing to the growing incidence of
diabetes. Growing awareness about diabetes is leading to improvement in its diagnosis and a consequent
increase in the number of diabetics taking medications. The self-monitoring of blood glucose has become
an integral part of diabetes management. Self-monitoring is done using blood glucose meters, test strips
and lancing devices. Patients can be easily trained to use these devices to check their blood glucose
levels.

An estimated 382 million patients are diagnosed with diabetes worldwide and the number is expected to
grow to 592 million by 2035. The annual cost of treatment of diabetes and its complications were
expected to rise to US$560 billion by FY2030. The global glucose monitoring market is expected to reach
US$14,306.4 million by FY2020, according to in-house forecasts. The global glucose monitoring market is
driven by major categories including Blood Glucose Meters, Blood Glucose Test Strips and Lancets.
Blood Glucose Test Strips are the major category in the glucose monitoring market. The global market for
Blood Glucose Test Strips is forecast to reach US$12,618.1 million by FY2020. This category is expected
to generate revenue of US$2,847.1 million by FY2020 in Asia Pacific; US$3,249 million in Europe; and
US$5,881.5 million in North America. The global blood glucose meters market is expected to reach US$
1,186.1 million by FY2020 and the global lancets market is expected to reach US$502.2 million by
FY2020.

The market is expected to register growth with the increasing diabetic population, the availability of
reimbursement for diabetes care devices and blood glucose test strips. Targeted marketing programs
would ensure that the company continues to improve its market share in the global diabetes care devices
market.

Threat

Government Regulations

The medical device markets are highly competitive and evolving, which could be a cause for concern to
the company. With the entry of many new players in this market, competition is expected to intensify in
the near future, which could result in price reductions. The company operates in a highly regulated
industry, where a variety of statutes and regulations are in place for the testing, manufacture and sale of
diagnostic products. The company has to obtain regulatory approvals before commercializing the
products. Failure to comply with the present or future regulations related to clinical, laboratory and
manufacturing practices may result in delayed approval of the device, product recalls, and cancellation of
permission to produce or sell the device. Increased regulation of the diagnostic market could increase the
company’s costs by increasing the time and cost of bringing new devices to market. The company’s
financial position could also be adversely affected by its inability to obtain or retain regulatory approvals
on a timely basis, as this will delay the commercialization of its products.

Stiff Competition

The company faces intense competition in the market for diabetic care devices. Its performance could be
affected by the competitive environment in the medical equipment sector and customer preferences. The
company’s competitors will continue to enhance their products or develop new products. Technological

DexCom Inc Page 20

© MarketLine
DexCom Inc
Company Overview

advances by any player in the market could render its present or future products obsolete or
uneconomical. The demand for its products depends on the competitive atmosphere, including the timely
development and introduction of new and competitive products and the company’s response to downward
pricing to sustain competition. Factors including changes in customer order patterns, changing
development programs or competitors’ new products could impact the company’s competitive ability. The
company might not achieve future growth projections, if it fails to successfully compete with its
competitors or develop new technologies.

Uncertain R&D Outcomes

Adverse or inconclusive results from preclinical testing or clinical trials may substantially delay or halt the
development of the company's various product candidates, consequently affecting its timeliness for
profitability. The outcome of clinical trials is always a subject of uncertainty. After the discovery of a new
compound, substantial amount of money and a great deal of time need to be invested to successfully
launch a new product. Moreover, it may become necessary to discontinue clinical development if the
effectiveness of a drug is not proven as initially expected, or if serious adverse effects arise. In addition,
medical devices are subject to legal restrictions in every country and authorization from regulatory
authorities is a prerequisite for a product launch in every country. It is difficult to accurately foresee when
approvals for a new product could be obtained.

DexCom Inc Page 21

© MarketLine
DexCom Inc
Company Overview

Top Competitors

TOP COMPETITORS
The following companies are the major competitors of DexCom Inc

Abbott Diabetes Care Inc

Abbott Laboratories
Bayer Corp
Becton Dickinson and Co
LifeScan Inc
MediSense Inc.
Medtronic Plc

DexCom Inc Page 22

© MarketLine
DexCom Inc
Company Overview

Company View

COMPANY VIEW
A part of the Management’s Discussion and Analysis of DexCom Inc is given below. It has been taken
from the company’s 10-K filing 2017.

Overview
We are a medical device company primarily focused on the design, development and commercialization
of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare
providers for the treatment of people with diabetes. Unless the context requires otherwise, the terms we,
us, our, the company, or DexCom refer to DexCom Inc and its subsidiaries.

From inception to 2006, we devoted substantially all of our resources to start-up activities, raising capital
and research and development, including product design, testing, manufacturing and clinical trials. Since
2006, we have devoted considerable resources to the commercialization of our continuous glucose
monitoring systems, including the G4 Platinum and G5 Mobile, as well as the continued research and
clinical development of our technology platform.

From inception through December 31, 2017, we have generated US$2.4 billion of product and
development grant and other (non-product) revenue, and we have incurred net losses in each year since
our inception in May 1999. As of December 31, 2017, we had an accumulated deficit of US$671.8 million.

We expect our losses to continue as we proceed with our commercialization and research and
development activities. We have financed our operations primarily through offerings of equity securities
and debt, and the sales of our products.

Financial Operations

Revenue

We sell our durable systems and disposable units through a direct sales force in the United States,
Canada and portions of Europe, and through distribution arrangements in the United States, Canada,
Australia, New Zealand, and in portions of Europe, Asia, Latin America, the Middle East and Africa. We
have contracts with certain distributors, the majority of whom stock our products, and we refer to these
distributors as Stocking Distributors, whereby the Stocking Distributors fulfill orders for our product from
their inventory. We also have contracts with certain distributors that do not stock our products, but rather
products are shipped directly to the customer by us on behalf of our distributor, and we refer to these
distributors as Drop-Ship Distributors. We expect that revenues we generate from the sales of our
products will fluctuate from quarter to quarter. We typically experience seasonality with lower sales in the
first quarter of each year, compared to the previous fourth quarter, related to annual insurance deductible
resets and unfunded flexible spending accounts.

Cost of Sales
Cost of sales includes direct labor and materials costs related to each product sold or produced, including
assembly, test labor and scrap, as well as factory overhead supporting our manufacturing operations.
Factory overhead includes facilities, material procurement and control, manufacturing engineering, quality

DexCom Inc Page 23

© MarketLine
DexCom Inc
Company Overview

assurance, supervision and management. These costs are primarily salary, fringe benefits, share-based
compensation, facility expense, supplies and purchased services. All of our manufacturing costs are
included in cost of sales.

Research and Development

Our research and development expenses primarily consist of engineering and research expenses related
to our continuous glucose monitoring technology, clinical trials, regulatory expenses, quality assurance
programs, materials and products for clinical trials. Research and development expenses are primarily
related to employee compensation, including salary, fringe benefits, share-based compensation, and
temporary employee expenses. We also incur significant expenses to operate our clinical trials including
clinical site reimbursement, clinical trial product and associated travel expenses. Our research and
development expenses also include fees for design services, contractors and development materials.

Selling, General and Administrative

Our selling, general and administrative expenses primarily consist of salary, fringe benefits and share-
based compensation for our executive, financial, sales, marketing, information technology and
administrative functions. Other significant expenses include commissions, marketing and advertising, IT
software license costs, insurance, professional fees for our outside legal counsel and independent
auditors, litigation expenses, patent application expenses, unoccupied facilities and consulting expenses.

Results of Operations
Fiscal year ended December 31, 2017 Compared to December 31, 2016.

Revenue, Cost of Sales and Gross Profit

Revenues increased US$145.2 million to US$718.5 million for the twelve months ended December 31,
2017 compared to US$573.3 million for the twelve months ended December 31, 2016 based primarily on
increased sales volume of our disposable sensors due to the continued growth of our installed base of
customers using our G4 PLATINUM and G5 Mobile systems and durable systems to both new and
existing customers. Revenue attributable to our disposable sensors and durable systems was
approximately 70% and 30%, respectively, of total revenue, for each of the twelve months ended
December 31, 2017 and 2016. Revenue from products shipped to our distributors, which are primarily
Stocking Distributors, for the twelve months ended December 31, 2017 was approximately US$538.0
million or 75% of our revenue compared to US$411.8 million or 72% of our total revenue for the twelve
months ended December 31, 2016.

Cost of sales increased US$31.5 million to US$226.4 million for the twelve months ended December 31,
2017 compared to US$194.9 million for the twelve months ended December 31, 2016, primarily due to
increased sales volume. The gross profit of US$492.1 million, or 68% for the twelve months ended
December 31, 2017 increased US$113.7 million compared to US$378.4 million, or 66% for the same
period in 2016, primarily due to increased revenue and a decrease in warranty costs primarily related to
the February 23, 2016 customer notification regarding the audible alarms and alerts associated with our
receivers which was classified as a voluntary Class 1 recall by the FDA and was closed by the FDA as of
August 11, 2017.

Research and Development.

Research and development expense increased US$29.3 million to US$185.4 million for the twelve

DexCom Inc Page 24

© MarketLine
DexCom Inc
Company Overview

months ended December 31, 2017, compared to US$156.1 million for the twelve months ended
December 31, 2016. The increase was primarily due to US$18.3 million in additional salaries, bonus and
payroll related costs, US$8.4 million of additional expensed equipment, and US$2.4 million of additional
clinical trial costs related to development of our future products.

Selling, General and Administrative.

Selling, general and administrative expense increased US$63.0 million to US$349.2 million for the twelve
months ended December 31, 2017, compared to US$286.2 million for the twelve months ended
December 31, 2016. The increase was primarily due to higher headcount related selling, marketing and
customer support costs to support revenue growth and the continued commercialization of our products.
Significant elements of the increase in selling, general, and administrative expenses included US$37.8
million in additional salaries, bonus, and payroll related costs, US$10.6 million of additional marketing
costs, US$4.4 million of additional software license costs, and US$1.5 million in additional consulting
fees.

Other Income (Expense). Other income was US$3.4 million for the twelve months ended December 31,
2017 compared to other expense of US$0.7 million for the twelve months ended December 31, 2016 and
is primarily related to foreign currency transaction gains and losses.
Interest Income. Interest income was US$3.3 million for the twelve months ended December 31, 2017
compared to US$0.4 million for the twelve months ended December 31, 2016 and is related to our
marketable securities portfolio.

Interest Expense.
Interest expense was US$12.8 million for the twelve months ended December 31, 2017 compared to
US$0.7 million for the twelve months ended December 31, 2016 and is related to our 2022 Notes and
Revolving Credit Agreement. The increase was primarily due to an additional US$11.1 million of interest
expense related to the 2022 Notes.

Income Tax Expense.

Income tax expense was USUS$1.6 million on a pre-tax loss of USUS$48.6 million, resulting in a
negative effective tax rate of 3% for the twelve months ended December 31, 2017, compared to income
tax expense of USUS$0.7 million on a pre-tax loss of US$64.9 million and a negative effective tax rate of
1% for the twelve months ended December 31, 2016. The effective tax rate at December 31, 2017
compared to December 31, 2016 increased due to a lower pre-tax net loss. The tax expense for both
periods is primarily due to withholding and other income tax expense in profitable jurisdictions.

DexCom Inc Page 25

© MarketLine
DexCom Inc
Company Overview

Locations And Subsidaries

LOCATIONS AND SUBSIDARIES

Head Office

DexCom Inc
6340 Sequence Drive
San Diego
California
San Diego
California
USA
Phone:1 858 2000200
Fax:1 302 6365454
www.dexcom.com

Other Locations and Subsidiaries

DexCom Inc Dxcm Sweden AB

Scheelevagen 17
Beta 6
SWE
SweetSpot Diabetes Care, Inc. TypeZero Technologies LLC
919 SW Taylor Street 919 Second Street South East
Suite 500 Charlottesville
Portland Virginia
Oregon Charlottesville
Portland Virginia
Oregon USA
USA Phone:1 434 2848919
Phone:1 503 2275272 www.typezero.com
www.sweetspotdiabetes.com

DexCom Inc Page 26

© MarketLine
DexCom Inc
Company Overview

Financial Overview

FINANCIAL OVERVIEW

Summarized Statement
*Note: Eliminations not included, all figures in Million except per share data.

Parameters Currency 2013 2014 2015 2016 2017

Income Statements
Total Revenue USD 160.00 259.20 402.00 573.30 718.50
Gross Profit USD 100.10 176.30 278.40 378.40 492.10
Operating Income USD -28.90 -21.50 -57.10 -63.90 -42.50
Net Income USD -29.80 -22.40 -57.60 -65.60 -50.20
Diluted Normalized EPS USD -0.42 -0.30 -0.72 -0.78 0.64
Balance Sheet
Total Current Assets USD 93.10 145.90 231.30 280.00 744.70
Total Assets USD 122.50 184.60 292.00 402.80 904.10
Total Current Liabilities USD 32.10 40.60 66.90 102.40 138.90
Total Liabilities USD 38.40 44.40 70.80 119.00 484.70
Total Equity USD 84.10 140.20 221.20 283.80 419.40
Total Common Shares Outstanding USD 72.50 77.30 81.70 84.60 87.00
Cash Flow
Cash from Operating Activities USD 2.40 23.60 49.00 56.20 92.00
Cash from Investing Activities USD 20.90 -16.80 -51.50 -55.90 -144.40
Cash from Financing Activities USD 11.80 21.80 16.80 8.10 399.10
Net Change in Cash USD 35.10 28.60 14.30 8.40 347.00

Detailed Statement
*Note: Eliminations not included, all figures in Million except per share data.

Parameters Currency 2013 2014 2015 2016 2017

Income Statements
Revenue USD 160.00 259.20 402.00 573.30 718.50
Total Revenue USD 160.00 259.20 402.00 573.30 718.50
Cost of Revenue, Total USD 59.90 82.90 123.60 194.90 226.40
Gross Profit USD 100.10 176.30 278.40 378.40 492.10
Selling/ General/ Admin. Expenses, USD 84.20 128.40 198.00 286.20 349.20
Total
Research & Development USD 44.80 69.40 137.50 156.10 185.40
Unusual Expense (Income) USD 0.00 0.00 0.00 0.00 0.00

DexCom Inc Page 27

© MarketLine
DexCom Inc
Company Overview

Total Operating Expense USD 188.90 280.70 459.10 637.20 761.00

Operating Income USD -28.90 -21.50 -57.10 -63.90 -42.50
Other, Net USD 0.00 0.00 0.00 -0.70 3.40
Net Income Before Taxes USD -29.80 -22.30 -57.50 -64.90 -48.60
Provision for Income Taxes USD 0.00 0.10 0.10 0.70 -104.10
Net Income After Taxes USD -29.80 -22.40 -57.60 -65.60 55.50
Net Income Before Extra. Items USD -29.80 -22.40 -57.60 -65.60 55.50
Total Extraordinary Items USD 0.00 0.00 0.00 0.00 -105.70
Net Income USD -29.80 -22.40 -57.60 -65.60 -50.20
Income Available to Com Excl USD -29.80 -22.40 -57.60 -65.60 55.50
ExtraOrd
Income Available to Com Incl USD -29.80 -22.40 -57.60 -65.60 -50.20
ExtraOrd
Dilution Adjustment USD 0.00 0.00 0.00 0.00 0.00
Diluted Net Income USD -29.80 -22.40 -57.60 -65.60 -50.20
Diluted Weighted Average Shares USD 71.10 75.20 79.80 83.60 86.30
Diluted EPS Excluding ExtraOrd USD -0.42 -0.30 -0.72 -0.78 0.64
Items
Diluted Normalized EPS USD -0.42 -0.30 -0.72 -0.78 0.64
DPS - Common Stock Primary Issue USD 0.00 0.00 0.00 0.00 0.00
Balance Sheet
Cash & Equivalents USD 43.20 71.80 86.10 94.50 441.50
Short Term Investments USD 11.40 11.80 29.10 29.20 107.10
Cash and Short Term Investments USD 54.60 83.60 115.20 123.70 548.60
Accounts Receivable - Trade, Net USD 26.10 42.40 74.10 101.70 134.30
Total Receivables, Net USD 26.10 42.40 74.10 101.70 134.30
Total Inventory USD 9.00 16.00 35.20 45.40 45.20
Prepaid Expenses USD 3.40 3.90 6.80 9.20 16.60
Total Current Assets USD 93.10 145.90 231.30 280.00 744.70
Property/ Plant/ Equipment, Total - USD 47.30 64.00 92.90 156.60 200.40
Gross
Accumulated Depreciation, Total USD -26.60 -32.80 -38.20 -47.20 -54.80
Property/ Plant/ Equipment, Total - USD 20.70 31.20 54.70 109.40 145.60
Net
Goodwill, Net USD 3.20 3.20 3.70 11.30 12.10
Intangibles, Net USD 3.60 2.70 2.20 0.20 0.00
Other Long Term Assets, Total USD 1.90 1.60 0.10 1.90 1.70
Total Assets USD 122.50 184.60 292.00 402.80 904.10
Accounts Payable USD 4.20 9.90 19.00 24.50 46.70
Accrued Expenses USD 25.00 27.70 44.80 77.00 89.00

DexCom Inc Page 28

© MarketLine
DexCom Inc
Company Overview

Notes Payable/ Short Term Debt USD 0.00 0.00 0.00 0.00 0.00
Current Port. of LT Debt/ Capital USD 2.20 2.30 2.30 0.00 0.00
Leases
Other Current liabilities, Total USD 0.70 0.70 0.80 0.90 3.20
Total Current Liabilities USD 32.10 40.60 66.90 102.40 138.90
Long Term Debt USD 4.60 2.30 0.00 0.00 327.60
Capital Lease Obligations USD 0.00 0.00 0.00 6.00 6.70
Total Long Term Debt USD 4.60 2.30 0.00 6.00 334.30
Total Debt USD 6.80 4.60 2.30 6.00 334.30
Other Liabilities, Total USD 1.70 1.50 3.90 10.60 11.50
Total Liabilities USD 38.40 44.40 70.80 119.00 484.70
Redeemable Preferred Stock, Total USD 0.00 0.00 0.00 0.00 0.00
Common Stock, Total USD 0.00 0.10 0.10 0.10 0.10
Additional Paid-In Capital USD 559.50 638.00 776.80 905.70 1,093.70
Retained Earnings (Accumulated USD -475.40 -497.80 -555.40 -621.00 -671.80
Deficit)
Unrealized Gain (Loss) USD 0.00 0.00 0.00 0.00 0.00
Other Equity, Total USD 0.00 -0.10 -0.30 -1.00 -2.60
Total Equity USD 84.10 140.20 221.20 283.80 419.40
Total Liabilities & Shareholders' USD 122.50 184.60 292.00 402.80 904.10
Equity
Total Common Shares Outstanding USD 72.50 77.30 81.70 84.60 87.00
Cash Flow
Net Income/ Starting Line USD -29.80 -22.40 -57.60 -65.60 -50.20
Depreciation/ Depletion USD 7.00 8.40 10.80 15.00 16.10
Non-Cash Items USD 28.00 50.40 120.20 113.10 123.50
Changes in Working Capital USD -2.80 -12.80 -24.40 -6.30 2.60
Cash from Operating Activities USD 2.40 23.60 49.00 56.20 92.00
Capital Expenditures USD -7.90 -16.20 -33.30 -55.70 -66.00
Other Investing Cash Flow Items, USD 28.80 -0.60 -18.20 -0.20 -78.40
Total
Cash from Investing Activities USD 20.90 -16.80 -51.50 -55.90 -144.40
Issuance (Retirement) of Stock, Net USD 12.00 24.00 19.10 10.40 10.10
Issuance (Retirement) of Debt, Net USD -0.20 -2.20 -2.30 -2.30 389.00
Cash from Financing Activities USD 11.80 21.80 16.80 8.10 399.10
Foreign Exchange Effects USD 0.00 0.00 0.00 0.00 0.30
Net Change in Cash USD 35.10 28.60 14.30 8.40 347.00
Cash Interest Paid USD 0.50 0.40 0.30 0.10 2.40
Cash Taxes Paid USD 0.00 0.00 0.10 0.10 1.40

DexCom Inc Page 29

© MarketLine
DexCom Inc
Company Overview

Summarized Interim Statement

Income Statements Currency Dec-2017 (3 Mar-2018 (3 Jun-2018 (3 Sep-2018 (3

Months) Months) Months) Months)
Total Revenue USD 221.00 184.40 242.50 266.70
Gross Profit USD 153.50 118.90 153.60 168.60
Operating Income USD 12.00 -30.70 -4.90 13.90
Net Income USD -9.40 -24.20 30.20 46.60
Diluted Normalized EPS USD 1.11 -0.28 0.34 0.52
Balance Sheet Currency Dec-2017 Mar-2018 Jun-2018 Sep-2018
Total Current Assets USD 744.70 729.30 836.00 914.10
Total Assets USD 904.10 896.80 1,007.50 1,114.30
Total Current Liabilities USD 138.90 125.10 170.80 193.90
Total Liabilities USD 484.70 475.10 525.40 552.10
Total Equity USD 419.40 421.70 482.10 562.20
Total Common Shares Outstanding USD 87.00 88.10 87.30 88.80
Cash Flow Currency Dec-2017 Mar-2018 (3 Jun-2018 (6 Sep-2018 (9
(12 Months) Months) Months) Months)
Cash from Operating Activities USD 92.00 -8.70 32.70 89.50
Cash from Investing Activities USD -144.40 -15.40 -175.30 -170.70
Cash from Financing Activities USD 399.10 4.20 3.40 8.80
Net Change in Cash USD 347.00 -20.80 -141.00 -73.80

Detailed Interim Statement

Income Statements Currency Dec-2017 (3 Mar-2018 (3 Jun-2018 (3 Sep-2018 (3

Months) Months) Months) Months)
Revenue USD 221.00 184.40 242.50 266.70
Total Revenue USD 221.00 184.40 242.50 266.70
Cost of Revenue, Total USD 67.50 65.50 88.90 98.10
Gross Profit USD 153.50 118.90 153.60 168.60
Selling/ General/ Admin. Expenses, USD 92.80 104.80 111.30 104.60
Total
Research & Development USD 48.70 44.80 47.20 50.10
Total Operating Expense USD 209.00 215.10 247.40 252.80
Operating Income USD 12.00 -30.70 -4.90 13.90
Other, Net USD -0.10 2.60 -5.60 -1.60
Net Income Before Taxes USD 8.60 -24.00 29.60 44.80

DexCom Inc Page 30

© MarketLine
DexCom Inc
Company Overview

Provision for Income Taxes USD -87.70 0.20 -0.60 -1.80

Net Income After Taxes USD 96.30 -24.20 30.20 46.60
Net Income Before Extra. Items USD 96.30 -24.20 30.20 46.60
Net Income USD -9.40 -24.20 30.20 46.60
Income Available to Com Excl USD 96.30 -24.20 30.20 46.60
ExtraOrd
Income Available to Com Incl USD -9.40 -24.20 30.20 46.60
ExtraOrd
Diluted Net Income USD -9.40 -24.20 30.20 46.60
Diluted Weighted Average Shares USD 86.90 87.30 89.40 90.30
Diluted EPS Excluding ExtraOrd Items USD 1.11 -0.28 0.34 0.52
DPS - Common Stock Primary Issue USD 0.00 0.00 0.00 0.00
Diluted Normalized EPS USD 1.11 -0.28 0.34 0.52
Total Extraordinary Items USD -105.70 0.00 0.00 0.00
Balance Sheet Currency Dec-2017 Mar-2018 Jun-2018 Sep-2018
Cash & Equivalents USD 441.50 420.40 300.20 367.40
Short Term Investments USD 107.10 113.50 305.90 301.30
Cash and Short Term Investments USD 548.60 533.90 606.10 668.70
Accounts Receivable - Trade, Net USD 134.30 123.90 162.00 169.80
Total Receivables, Net USD 134.30 123.90 162.00 169.80
Total Inventory USD 45.20 51.60 46.20 55.20
Prepaid Expenses USD 16.60 19.90 21.70 20.40
Total Current Assets USD 744.70 729.30 836.00 914.10
Property/ Plant/ Equipment, Total - USD 200.40 211.30 222.30 241.90
Gross
Accumulated Depreciation, Total USD -54.80 -58.90 -65.50 -72.30
Property/ Plant/ Equipment, Total - USD 145.60 152.40 156.80 169.60
Net
Goodwill, Net USD 12.10 12.30 11.90 18.40
Other Long Term Assets, Total USD 1.70 2.80 2.80 12.20
Total Assets USD 904.10 896.80 1,007.50 1,114.30
Accounts Payable USD 46.70 38.90 59.90 57.70
Accrued Expenses USD 89.00 83.30 104.10 132.70
Notes Payable/ Short Term Debt USD 0.00 0.00 0.00 0.00
Other Current liabilities, Total USD 3.20 2.90 6.80 3.50
Total Current Liabilities USD 138.90 125.10 170.80 193.90
Long Term Debt USD 327.60 331.30 335.00 338.80
Capital Lease Obligations USD 6.70 7.40 7.30 7.30
Total Long Term Debt USD 334.30 338.70 342.30 346.10
Total Debt USD 334.30 338.70 342.30 346.10

DexCom Inc Page 31

© MarketLine
DexCom Inc
Company Overview

Other Liabilities, Total USD 11.50 11.30 12.30 12.10

Total Liabilities USD 484.70 475.10 525.40 552.10
Redeemable Preferred Stock, Total USD 0.00 0.00 0.00 0.00
Common Stock, Total USD 0.10 0.10 0.10 0.10
Additional Paid-In Capital USD 1,093.70 1,122.50 1,149.10 1,181.60
Retained Earnings (Accumulated USD -671.80 -696.00 -665.80 -619.20
Deficit)
Other Equity, Total USD -2.60 -4.90 -1.30 -0.30
Total Equity USD 419.40 421.70 482.10 562.20
Total Liabilities & Shareholders' Equity USD 904.10 896.80 1,007.50 1,114.30
Total Common Shares Outstanding USD 87.00 88.10 87.30 88.80
Cash Flow Currency Dec-2017 Mar-2018 (3 Jun-2018 (6 Sep-2018 (9
(12 Months) Months) Months) Months)
Net Income/ Starting Line USD -50.20 -24.20 6.00 52.60
Depreciation/ Depletion USD 16.10 6.00 12.70 20.50
Deferred Taxes 0.00 0.00 0.00 0.00
Non-Cash Items USD 123.50 20.00 12.30 8.70
Changes in Working Capital USD 2.60 -10.50 1.70 7.70
Cash from Operating Activities USD 92.00 -8.70 32.70 89.50
Capital Expenditures USD -66.00 -15.30 -25.60 -49.40
Other Investing Cash Flow Items, USD -78.40 -0.10 -149.70 -121.30
Total
Cash from Investing Activities USD -144.40 -15.40 -175.30 -170.70
Financing Cash Flow Items 0.00 0.00 -1.80 -1.80
Issuance (Retirement) of Stock, Net USD 10.10 4.20 5.20 10.60
Issuance (Retirement) of Debt, Net USD 389.00 0.00 0.00 0.00
Cash from Financing Activities USD 399.10 4.20 3.40 8.80
Foreign Exchange Effects USD 0.30 -0.90 -1.80 -1.40
Net Change in Cash USD 347.00 -20.80 -141.00 -73.80
Cash Taxes Paid USD -1.40 0.00 0.00 0.00
Cash Interest Paid USD 2.40 0.00 0.00 0.00

Capital Market Ratios

Key Ratios February 20,2019

P/E (Price/Earnings) Ratio 0.00
Enterprise Value/Sales 0.00
Enterprise Value/Total Assets 0.00
Dividend Yield 0.00

DexCom Inc Page 32

© MarketLine
DexCom Inc
Company Overview

Market Cap 5,766.89

Enterprise Value 0.00

Note: The above ratios are based on

the share price as of February
20,2019, they are absolute numbers
Annual Ratios

Key Ratios Unit 2013 2014 2015 2016 2017

Currency
Growth Ratios
Sales Growth % 60.16 62.00 55.09 42.61 25.33
Operating Income Growth % 0.00 0.00 0.00 0.00 0.00
EBITDA Growth % 0.00 0.00 0.00 0.00 0.00
Net Income Growth % 0.00 0.00 0.00 0.00 0.00
EPS Growth % 0.00 0.00 0.00 0.00 0.00
Working Capital Growth % 4.99 72.62 56.13 8.03 241.10
Equity Ratios
EPS (Earnings per Share) USD -0.42 -0.30 -0.72 -0.78 0.64
Dividend per Share USD 0.00 0.00 0.00 0.00 0.00
Book Value per Share USD 1.16 1.81 2.71 3.35 4.82
Cash Value per Share USD 0.60 0.93 1.05 1.12 5.07
Profitability Ratios
Gross Margin % 62.56 68.02 69.25 66.00 68.49
Operating Margin % -18.06 -8.29 -14.20 -11.15 -5.92
Net Profit Margin % -18.63 -8.64 -14.33 -11.44 -6.99
Profit Markup % 167.11 212.67 225.24 194.15 217.36
PBT Margin (Profit Before Tax) % -18.63 -8.60 -14.30 -11.32 -6.76
Return on Equity % -35.43 -15.98 -26.04 -23.11 -11.97
Return on Capital Employed % -31.97 -14.93 -25.37 -21.27 -5.55
Return on Assets % -26.08 -14.59 -24.17 -18.88 -7.68
Return on Fixed Assets % -98.30 -55.56 -94.07 -52.04 -26.66
Return on Working Capital % -47.38 -20.42 -34.73 -35.98 -7.02
Cost Ratios

DexCom Inc Page 33

© MarketLine
DexCom Inc
Company Overview

Operating Costs (% of Sales) % 118.06 108.29 114.20 111.15 105.92

Administration Costs (% of Sales) % 52.63 49.54 49.25 49.92 48.60
Liquidity Ratios
Current Ratio Absolute 2.90 3.59 3.46 2.73 5.36
Quick Ratio Absolute 2.62 3.20 2.93 2.29 5.04
Cash Ratio Absolute 1.70 2.06 1.72 1.21 3.95
Leverage Ratios
Debt to Equity Ratio Absolute 0.08 0.03 0.01 0.02 0.80
Net Debt to Equity Absolute -0.43 -0.48 -0.38 -0.31 -0.26
Debt to Capital Ratio Absolute 0.07 0.03 0.01 0.02 0.44
Efficiency Ratios
Asset Turnover Absolute 1.40 1.69 1.69 1.65 1.10
Fixed Asset Turnover Absolute 8.08 9.99 9.36 6.99 5.64
Inventory Turnover Absolute 7.30 6.63 4.83 4.84 5.00
Current Asset Turnover Absolute 1.87 2.17 2.13 2.24 1.40
Capital Employed Turnover Absolute 1.77 1.80 1.79 1.91 0.94
Working Capital Turnover Absolute 2.62 2.46 2.45 3.23 1.19
Revenue per Employee USD 0.00 0.00 0.00 0.00 313,755.46
Net Income per Employee USD 0.00 0.00 0.00 0.00 -21,921.40
Capex to Sales % 4.94 6.25 8.28 9.72 9.19
R&D to Sales % 28.00 26.77 34.20 27.23 25.80

Interim Ratios

Key Ratios Currency December March June September Ratio Type

01,2017 01,2018 01,2018 01,2018
EPS (Earnings per USD 1.11 -0.28 0.34 0.52 Equity Ratios
Share)
Book Value per Share USD 4.82 4.79 5.52 6.33 Equity Ratios
Current Ratio Absolute 5.36 5.83 4.90 4.71 Liquidity Ratios

DexCom Inc Page 34

© MarketLine
 A Progressive Digital Media business

John Carpenter House, John Carpenter Street, London, United Kingdom, EC4Y 0AN
T: +44 (0) 203 377 3042 | F: +44 (0) 870 134 4371 | E: reachus@marketline.com | W: www.marketline.com